why choose us

First received: July 21, 2022

Clinical Trial: Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive Enhancing IDH-1 Mutant Astrocytomas

Study Status: Completed

Recruit Status: RECRUITING

Condition: Astrocytoma

Study Type: INTERVENTIONAL


Official Title: A Phase 1, Safety Lead-in and Randomized, Open-label, Perioperative Study of Vorasidenib in Combination With Pembrolizumab in Subjects With Recurrent or Progressive Enhancing IDH-1 Mutant Astrocytomas

Brief Summary: Vorasidenib in combination with pembrolizumab in participants with recurrent or progressive enhancing isocitrate dehydrogenase-1 (IDH-1) mutant astrocytomas.

Read more